CD34 and Friedreich ataxia: Although efficacies of gene targeting achieved in FA CD34+ cells are still significantly lower compared to the transduction efficacy achieved by lentiviral vectors (Jacome et al, 2009; Becker et al, 2010; Gonzalez‐Murillo et al, 2010), our results suggest that gene editing could be applicable to BMF syndromes such as FA, in which a selection advantage of edited cells could take place, as we already demonstrated in primary fibroblasts and iPSCs from FA patients (Rio et al, 2014).